Overview

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Status:
Recruiting

Trial end date:
2027-10-29

Target enrollment:

Participant gender:

Summary

This is a Phase III double-blind, placebo-controlled study of Durvalumab versus Placebo in patients with stage II-III NSCLC who are MRD-positive following curative intent therapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Durvalumab